Polyneuropathy is a prevalent, disabling condition affecting 2% to 7% of the population
1,2; however, a definitive cause is lacking in 30% of patients.
3,4 The most common etiologic condition is diabetes, with a similar prevalence in patients with types 1 and 2 diabetes.
5-9 In patients with type 1 diabetes, enhanced glucose control reduces the incidence of polyneuropathy substantially, but in those with type 2 diabetes, the effect does not reach statistical significance.
10 Therefore, factors other than glucose control are likely to be involved in the development of type 2 diabetic polyneuropathy.
11 These same factors may also explain why patients are diagnosed with idiopathic polyneuropathy. Components of metabolic syndrome are potential aspects since these cardiovascular risk factors cluster with hyperglycemia.